Markets
JPMorgan Resumes Legend Biotech Coverage With Neutral Rating: What Traders Need to Know
JPMorgan has re-initiated coverage of Legend Biotech with a neutral rating, signaling cautious optimism but no clear near-term catalyst. Here is what the move means for active traders and longer-term investors watching LEGN.